High-throughput Viable Circulating Tumor Cell Isolation Using Tapered-slit Membrane Filter-based Chipsets in the Differential Diagnosis of Ovarian Tumors

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jun 4

PMID 38833451

Authors

Nam Kyeong Kim

Dong Hoon Suh

Kidong Kim

Jae Hong No

Yong Beom Kim

Minki Kim

Young-Ho Cho

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the diagnostic performance of circulating tumor cells (CTCs) using tapered-slit membrane filter (TSF)-based chipsets for the differential diagnosis of adnexal tumors.

Methods: A total of 230 women with indeterminate adnexal tumors were prospectively enrolled. The sensitivity, specificity, and accuracy of the CTC-detecting chipsets were analyzed according to postoperative pathological results and compared with those of cancer antigen (CA)-125 and imaging tests.

Results: Eighty-one (40.3%) benign tumors, 31 (15.4%) borderline tumors, and 89 (44.3%) ovarian cancers were pathologically confirmed. The sensitivity, specificity, and accuracy of CTC-detecting chipsets (75.3%, 58.0%, and 67.1%) for differentiating ovarian cancer from benign tumors were similar to CA-125 (78.7%, 53.1%, and 66.5%), but lower than CT/MRI (94.2%, 77.9%, and 86.5%). "CTC or CA125" showed increased sensitivity (91.0%) and "CTC and CA-125" revealed increased specificity (77.8%), comparable to CT/MRI. CTC detection rates in stage I/II and stage III/IV ovarian cancers were 69.6% and 81.4%, respectively. The sensitivity to detect high-grade serous (HGS) cancer from benign tumors (84.6%) was higher than that to detect non-HGS cancers (68.0%).

Conclusion: Although the diagnostic performance of the TSF platform to differentiate between ovarian cancer and benign tumors did not yield significant results, the combination of CTC and CA-125 showed promising potential in the diagnostic accuracy of ovarian cancer.

References

Yousefi M, Rajaie S, Keyvani V, Bolandi S, Hasanzadeh M, Pasdar A . Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy. Sci Rep. 2021; 11(1):10524. PMC: 8131620. DOI: 10.1038/s41598-021-88780-w. View

Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C . EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011; 64(5):415-20. PMC: 3088404. DOI: 10.1136/jcp.2011.090274. View

Szczerba A, Sliwa A, Pieta P, Jankowska A . The Role of Circulating Tumor Cells in Ovarian Cancer Dissemination. Cancers (Basel). 2022; 14(24). PMC: 9775737. DOI: 10.3390/cancers14246030. View

Lou E, Vogel R, Teoh D, Hoostal S, Grad A, Gerber M . Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. Lab Med. 2018; 49(2):134-139. PMC: 6251585. DOI: 10.1093/labmed/lmx084. View

Kolostova K, Matkowski R, Jedryka M, Soter K, Cegan M, Pinkas M . The added value of circulating tumor cells examination in ovarian cancer staging. Am J Cancer Res. 2016; 5(11):3363-75. PMC: 4697683. View

Charkhchi P, Cybulski C, Gronwald J, Wong F, Narod S, Akbari M . CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020; 12(12). PMC: 7763876. DOI: 10.3390/cancers12123730. View

Ngu S, Chai Y, Choi K, Leung T, Li J, Kwok G . Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules. Cancers (Basel). 2022; 14(3). PMC: 8833816. DOI: 10.3390/cancers14030810. View

Zheng P, Zheng P, Chen G . Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database. Front Med (Lausanne). 2021; 8:756401. PMC: 8650058. DOI: 10.3389/fmed.2021.756401. View

Suh D, Kim M, Choi J, Bu J, Kang Y, Kwon B . Circulating tumor cells in the differential diagnosis of adnexal masses. Oncotarget. 2017; 8(44):77195-77206. PMC: 5652773. DOI: 10.18632/oncotarget.20428. View

10.

Millner L, Linder M, Valdes Jr R . Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013; 43(3):295-304. PMC: 5060940. View

11.

Foti P, Attina G, Spadola S, Caltabiano R, Farina R, Palmucci S . MR imaging of ovarian masses: classification and differential diagnosis. Insights Imaging. 2015; 7(1):21-41. PMC: 4729709. DOI: 10.1007/s13244-015-0455-4. View

12.

Ataseven B, Chiva L, Harter P, Gonzalez-Martin A, du Bois A . FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol. 2016; 142(3):597-607. DOI: 10.1016/j.ygyno.2016.06.013. View

13.

Kolostova K, Pinkas M, Jakabova A, Pospisilova E, Svobodova P, Spicka J . Molecular characterization of circulating tumor cells in ovarian cancer. Am J Cancer Res. 2016; 6(5):973-80. PMC: 4889713. View

14.

Dirix L, Buys A, Oeyen S, Peeters D, Liegeois V, Prove A . Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022; 193(2):437-444. PMC: 9090706. DOI: 10.1007/s10549-022-06585-5. View

15.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu E . Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J Gynecol Oncol. 2014; 25(3):221-8. PMC: 4102741. DOI: 10.3802/jgo.2014.25.3.221. View

16.

Franken B, de Groot M, Mastboom W, Vermes I, van der Palen J, Tibbe A . Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012; 14(5):R133. PMC: 4053111. DOI: 10.1186/bcr3333. View

17.

Yadav A, Kumar A, Siddiqui M . Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. World J Clin Oncol. 2022; 12(12):1169-1181. PMC: 8716996. DOI: 10.5306/wjco.v12.i12.1169. View

18.

Hada A, Han L, Chen Y, Hu Q, Yuan Y, Liu L . Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses. J Ovarian Res. 2020; 13(1):46. PMC: 7183707. DOI: 10.1186/s13048-020-00643-6. View

19.

Gallo M, De Luca A, Maiello M, DAlessio A, Esposito C, Chicchinelli N . Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl Lung Cancer Res. 2017; 6(4):486-498. PMC: 5583074. DOI: 10.21037/tlcr.2017.05.07. View

20.

Liu J, Kindelberger D, Doyle C, Lowe A, Barry W, Matulonis U . Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013; 131(2):352-6. DOI: 10.1016/j.ygyno.2013.08.006. View